NO20012812L - Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid - Google Patents

Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid

Info

Publication number
NO20012812L
NO20012812L NO20012812A NO20012812A NO20012812L NO 20012812 L NO20012812 L NO 20012812L NO 20012812 A NO20012812 A NO 20012812A NO 20012812 A NO20012812 A NO 20012812A NO 20012812 L NO20012812 L NO 20012812L
Authority
NO
Norway
Prior art keywords
polypeptides
vaccine
dna sequences
polynucleotide
polypeptide
Prior art date
Application number
NO20012812A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012812D0 (no
Inventor
Peter Probst
Ajay Bhatia
Yasir A W Skeiky
Steven P Fling
Shyian Jen
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/208,277 external-priority patent/US6166177A/en
Priority claimed from US09/288,594 external-priority patent/US6447779B1/en
Priority claimed from US09/410,568 external-priority patent/US6555115B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of NO20012812D0 publication Critical patent/NO20012812D0/no
Publication of NO20012812L publication Critical patent/NO20012812L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20012812A 1998-12-08 2001-06-07 Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid NO20012812L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/208,277 US6166177A (en) 1998-12-08 1998-12-08 Compounds and methods for the treatment and diagnosis of chlamydial infection
US09/288,594 US6447779B1 (en) 1998-12-08 1999-04-08 Compounds for the diagnosis of Chlamydial infection
US09/410,568 US6555115B1 (en) 1998-12-08 1999-10-01 Compounds and methods for treatment and diagnosis of chlamydial infection
US42657199A 1999-10-22 1999-10-22
PCT/US1999/029012 WO2000034483A2 (fr) 1998-12-08 1999-12-08 Composes et procedes pour le traitement et le diagnostic d'infections par le chlamydia

Publications (2)

Publication Number Publication Date
NO20012812D0 NO20012812D0 (no) 2001-06-07
NO20012812L true NO20012812L (no) 2001-08-02

Family

ID=27498718

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20012812A NO20012812L (no) 1998-12-08 2001-06-07 Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid
NO20101293A NO20101293L (no) 1998-12-08 2010-09-14 Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20101293A NO20101293L (no) 1998-12-08 2010-09-14 Vaksinesammensetning og vaksine samt anvendelse av polypeptid og polynukletid

Country Status (18)

Country Link
EP (5) EP1144642B1 (fr)
JP (2) JP2002531129A (fr)
KR (4) KR20100132086A (fr)
CN (1) CN100365120C (fr)
AT (1) ATE469222T1 (fr)
AU (2) AU769293B2 (fr)
BR (1) BR9916020A (fr)
CA (2) CA2354232A1 (fr)
DE (1) DE69942426D1 (fr)
ES (1) ES2346832T3 (fr)
HK (1) HK1044020B (fr)
HU (1) HUP0400719A3 (fr)
IL (5) IL143531A0 (fr)
MX (1) MXPA01005813A (fr)
NO (2) NO20012812L (fr)
NZ (1) NZ512246A (fr)
TR (1) TR200102500T2 (fr)
WO (1) WO2000034483A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
AU754122B2 (en) * 1998-04-20 2002-11-07 State of Oregon, acting by and through The State Board Of Higher Education, on behalf of Oregon State University, The Chlamydia proteins and their uses
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
EP1105489A1 (fr) 1998-08-20 2001-06-13 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine pomp91a de chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3790900A (en) 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002541766A (ja) 1998-12-28 2002-12-10 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP2172214A3 (fr) 1999-03-12 2011-03-16 Aventis Pasteur Limited Antigènes de Chlamydia et fragments d'ADN correspondants, et leurs utilisations
WO2000066739A2 (fr) 1999-05-03 2000-11-09 Aventis Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
CA2385325C (fr) 1999-09-20 2012-04-10 Aventis Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisations
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1240331B1 (fr) 1999-12-22 2010-04-07 Aventis Pasteur Limited Antigenes anti- chlamydia, fragments d'adn correspondants et leurs utilisations
AU2001255596A1 (en) * 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1282718B1 (fr) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisations de tels antigenes
ATE440861T1 (de) * 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB2378056A (en) * 2001-07-27 2003-01-29 William Dixon Electrical connection device
ES2386386T3 (es) * 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
JP2004261017A (ja) * 2003-02-27 2004-09-24 Arkray Inc クラミジア・トラコマティスの検出方法およびそのためのキット
CN101184504A (zh) * 2005-03-31 2008-05-21 葛兰素史密丝克莱恩生物有限公司 针对衣原体感染的疫苗
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
CA2664236A1 (fr) * 2006-10-04 2008-04-10 Glaxosmithkline Biologicals S.A. Vaccins contre l'infection a chlamydia
EP2162460A4 (fr) * 2007-06-14 2012-06-06 Emergent Product Dev Gaithersburg Inc Vaccins destinés à lutter contre une infection à chlamydia
WO2010100632A2 (fr) 2009-03-06 2010-09-10 Novartis Ag Antigènes de chlamydia
WO2011118496A1 (fr) 2010-03-23 2011-09-29 和光純薬工業株式会社 Amorce et sonde conçues pour détecter chlamydia trachomatis et procédé de détection de chlamydia trachomatis les utilisant
CN109563481B (zh) * 2016-07-13 2024-01-05 俄亥俄州创新基金会 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (fr) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1001032A3 (fr) 1989-08-18 2005-02-23 Chiron Corporation Rétrovirus de recombinaison apportant des constructions de vecteur à des cellules cibles
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5840297A (en) * 1993-03-19 1998-11-24 Johns Hopkins University Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CN100365017C (zh) * 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
MX9703676A (es) * 1994-11-17 1998-03-31 Maxim Pharm Inc Inmunogenos para estimular la inmunidad de las mucosas.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (fr) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. Procede ameliore pour obtenir des sequences d'adn complementaire longues
EP0871747A1 (fr) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation a mediation par cellules dendritiques modifiees par des genes
WO1998002546A2 (fr) * 1996-07-12 1998-01-22 University Of Manitoba VACCINATION A L'ADN CONTRE L'INFECTION DUE A $i(CHLAMYDIA)
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
KR100760221B1 (ko) * 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
MXPA01001639A (es) * 1998-08-20 2004-09-06 Connaught Lab Antigenos de chlamydia y los correspondientes fragmentos de adn y usos de los mismos.
EP1133572A4 (fr) 1998-11-12 2005-06-15 Univ California Sequence genomique de chlamydia pneumoniae
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
CN100365120C (zh) 1998-12-08 2008-01-30 科里克萨有限公司 用于治疗及诊断衣原体感染的化合物和方法
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
WO2000066739A2 (fr) 1999-05-03 2000-11-09 Aventis Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisation de ceux-ci
CA2385325C (fr) 1999-09-20 2012-04-10 Aventis Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisations
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2937907C (fr) * 1999-09-28 2017-08-22 Geneohm Sciences Canada Inc. Acides nucleiques, methodes et trousses de detection de campylobacter
EP1240331B1 (fr) 1999-12-22 2010-04-07 Aventis Pasteur Limited Antigenes anti- chlamydia, fragments d'adn correspondants et leurs utilisations
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1282718B1 (fr) 2000-05-08 2006-12-20 Sanofi Pasteur Limited Antigenes de chlamydia, fragments d'adn correspondants et utilisations de tels antigenes
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US9103184B2 (en) 2013-03-08 2015-08-11 Tejas Research & Engineering, Llc Inflow control valve
WO2016023894A1 (fr) 2014-08-11 2016-02-18 U3 Pharma Gmbh Anticorps anti-fgfr4 humain

Also Published As

Publication number Publication date
EP2277892A3 (fr) 2011-04-27
WO2000034483A3 (fr) 2001-11-01
KR100829407B1 (ko) 2008-05-15
NO20012812D0 (no) 2001-06-07
IL209114A0 (en) 2011-01-31
PL363147A1 (en) 2004-11-15
CN1333832A (zh) 2002-01-30
HK1044020B (zh) 2008-10-31
MXPA01005813A (es) 2002-05-06
CA2354232A1 (fr) 2000-06-15
IL143531A0 (en) 2002-04-21
JP2002531129A (ja) 2002-09-24
AU769293B2 (en) 2004-01-22
IL209115A0 (en) 2011-01-31
AU2004201702B2 (en) 2007-07-05
CN100365120C (zh) 2008-01-30
NZ512246A (en) 2003-12-19
EP2218733A1 (fr) 2010-08-18
WO2000034483A2 (fr) 2000-06-15
KR20070108263A (ko) 2007-11-08
AU1935800A (en) 2000-06-26
CA2746535A1 (fr) 2000-06-15
IL209116A0 (en) 2011-01-31
ATE469222T1 (de) 2010-06-15
NO20101293L (no) 2001-08-02
ES2346832T3 (es) 2010-10-20
WO2000034483A9 (fr) 2001-07-05
IL209113A0 (en) 2011-01-31
EP2277893A2 (fr) 2011-01-26
EP2223935A2 (fr) 2010-09-01
EP2277892A2 (fr) 2011-01-26
DE69942426D1 (de) 2010-07-08
EP2277893A3 (fr) 2011-03-30
HUP0400719A3 (en) 2010-08-30
KR20100132086A (ko) 2010-12-16
BR9916020A (pt) 2002-01-22
TR200102500T2 (tr) 2002-03-21
KR20090088972A (ko) 2009-08-20
KR20010101152A (ko) 2001-11-14
EP1144642A2 (fr) 2001-10-17
EP1144642B1 (fr) 2010-05-26
JP2011036258A (ja) 2011-02-24
HUP0400719A2 (hu) 2004-07-28
AU2004201702A1 (en) 2004-05-20
EP2223935A3 (fr) 2010-11-24
HK1044020A1 (zh) 2002-10-04

Similar Documents

Publication Publication Date Title
IL209114A0 (en) Pharmaceutical compositions and vaccines comprising an antigenic portion of a chlamydia protein, and uses thereof
NZ518917A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
PL365951A1 (pl) Związki oraz sposoby leczenia i diagnozowania infekcji Chlamydia
AU2001255596A1 (en) Compounds and methods for treatment and diagnosis of chlamydial infection
WO1998042740A3 (fr) COMPOSES ET PROCEDES DE DIAGNOSTIC ET DE TRAITEMENT DE L'INFECTION PAR $i(EHRLICHIA)
WO2001062893A3 (fr) Composes et methodes de diagnostic et d'immunotherapie de la tuberculose
WO2003041560A3 (fr) Composes et methodes permettant de traiter et de diagnostiquer l'infection a chlamydia
WO2003086308A3 (fr) Compositions et procedes pour le diagnostic et le traitement de l'infection du virus de l'herpes simplex
WO1998053076A3 (fr) Composes permettant de diagnostiquer la tuberculose et leurs procedes d'utilisation
WO2000000615A3 (fr) COMPOSES ET PROCEDES SERVANT A DIAGNOSTIQUER ET A TRAITER L'INFECTION PAR $i(EHRLICHIA)
DE60125537D1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
WO2001085949A3 (fr) Composes et procedes de diagnostic et de traitement de l'infection par une ehrlichia
EP0834567A3 (fr) Composés et méthodes pour le diagnostique et le traitement d'infections à Babesia microti
WO2003020108A3 (fr) Compositions et procedes destines a diagnostiquer et a traiter une infection par le virus de l'herpes simplex
WO2002053016A3 (fr) Composes et methodes permettant de diagnostiquer et de traiter une infection par babesia
WO2001085947A3 (fr) Composes et techniques destines au diagnostic et au traitement de l'infection par b. microti

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application